{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.5","spread":"50.5","upperLimit":"61.7","value":"56.2"},{"groupId":"OG001","lowerLimit":"35.2","spread":"35.2","upperLimit":"46.2","value":"40.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"315"},{"groupId":"OG001","value":"320"}],"units":"Participants"}],"description":"Objective response rate was measured as the proportion of patients who achieved a confirmed partial response or better during the course of the study. Response to study therapy was assessed using EBMT Criteria and confirmed by Independent Adjudication Review.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants will receive vorinostat four 100 mg capsules (400 mg total) orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"OG000","title":"Vorinostat + Bortezomib"},{"description":"Participants will receive four placebo capsules orally 0-30 minutes after a meal on Days 1 through 14 of a 21-day treatment cycle and bortezomib 1.3 mg/m\\^2 by intravenous injection on Days 1, 4, 8, and 11 of a 21-day treatment cycle.","id":"OG001","title":"Placebo + Bortezomib"}],"paramType":"NUMBER","populationDescription":"The analysis population includes all randomized participants who received ≥1 dose of study medication.","reportingStatus":"POSTED","timeFrame":"Baseline and at the end of each 21-day Cycle assessed up to 32 months (final study analysis)","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}